Even without combining with chemotherapy, pharmacologic blockade using CXCR4 antagonists, such as AMD3100 (plerixafor), AMD3465, or through monoclonal antibodies, has demonstrated the ability to reduce tumour burden, delay metastasis, and enhance chemosensitivity in preclinical TNBC models [19]. This evidence concerns the gene CXCR4 and neoplasm.